Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inhibikase Therapeutics, Inc. filings document the disclosure record for a Nasdaq-listed clinical-stage pharmaceutical company developing IKT-001 for pulmonary arterial hypertension. Form 8-K reports cover operating and financial results, Regulation FD materials, clinical and regulatory updates for IMPROVE-PAH, and exhibits furnished with company press releases and corporate presentations.
Proxy and annual-meeting filings address board elections, auditor ratification, equity incentive plan amendments, executive compensation and shareholder voting results. Other disclosures describe the company's common stock, Nasdaq listing, inducement equity awards, material agreements, and capital-structure matters involving common stock and warrant securities.
Inhibikase Therapeutics, Inc. (IKT) furnished an updated corporate overview describing its lead candidate IKT-001, a novel oral prodrug of imatinib in a pivotal Phase 3 program for pulmonary arterial hypertension (PAH), a rare disease with about 30% 5‑year mortality and a $8.3 billion global market in 2025.
The company highlights that imatinib previously showed antiproliferative efficacy in PAH, including a placebo‑adjusted 45‑meter improvement in 6‑minute walk distance and a 32% reduction in pulmonary vascular resistance, but was limited by tolerability. IKT-001 is designed to retain efficacy while improving gastrointestinal tolerability and is being studied in the IMPROVE‑PAH Phase 3 trial with a 12‑week dose‑titration design across 26 countries and 46 of a planned ~180 sites active. The program has Orphan Drug Designation, is being advanced under a 505(b)(2) regulatory pathway, and the company indicates expected cash runway through the Phase 3 Part B topline readout, assuming full and timely exercise of outstanding Series A and B warrants.
Inhibikase Therapeutics, Inc. (IKT) reported that its Audit Committee dismissed CohnReznick LLP as independent registered public accounting firm on August 21, 2026, and, effective immediately thereafter, appointed Deloitte & Touche LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2026. CohnReznick’s audit reports for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications, and the company states there were no disagreements on accounting principles, financial disclosure, or audit scope. CohnReznick had previously advised that a material weakness in internal control over financial reporting existed during the year ended December 31, 2024; this was earlier disclosed and described as remediated by prior management by the quarter ended September 30, 2024. Other than that reportable event, the company reports no additional reportable events during 2025, 2024, or subsequent interim periods.
Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of 10,320,875 shares of Inhibikase Therapeutics, Inc. common stock through warrants, representing 6.9% of the class. This percentage is based on 139,535,900 shares outstanding as of August 4, 2026 and assumes exercise of the warrants held by the reporting group.
The Master Fund directly holds (i) pre-funded warrants for 790,000 shares at an exercise price of $0.001 per share, (ii) common warrants for 3,357,211 shares at $1.37 per share, and (iii) common warrants for 6,173,664 shares at $1.49 per share. The warrants contain a 9.99% beneficial ownership limitation, which currently permits exercise for up to 10,320,875 shares. Perceptive Advisors serves as investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of Inhibikase Therapeutics common stock. As of June 30, 2026, they may be deemed to beneficially own 5,810,487 shares, representing 4.30% of the outstanding common stock.
The position includes 3,108,624 shares that may be acquired within sixty days through the exercise of convertible securities, held in funds and separately managed accounts under Nantahala’s control. The Reporting Persons have no sole voting or dispositive power, but share voting and dispositive power over all 5,810,487 shares and indicate ownership of five percent or less of the class.
Sands Capital Life Sciences Pulse Fund II, L.P., together with related entities and Frank M. Sands, reports beneficial ownership of 13,018,965 shares of Inhibikase Therapeutics, Inc. common stock, representing 9.3% of the class based on 139,535,900 shares outstanding as of August 4, 2026. The shares are held with shared voting and dispositive power among the reporting persons.
The group also holds a Series A-1 warrant for 5,475,000 shares and a Series B-1 warrant for 10,068,120 shares, acquired under an October 9, 2024 securities purchase agreement. These warrants are not included in the reported ownership because they are not exercisable within 60 days and are subject to a 19.99% beneficial ownership limitation, which restricts exercises that would push ownership above that level. Each reporting person and the related general partners disclaim beneficial ownership beyond their pecuniary interest.
Inhibikase Therapeutics is a clinical-stage company focused on IKT-001, a prodrug of imatinib for pulmonary arterial hypertension, now in a single pivotal global Phase 3 IMPROVE-PAH trial with 26 country approvals and 43 sites activated. For the six months ended June 30, 2026, it reported a net loss of $35.97 million, compared with $23.59 million a year earlier, driven mainly by higher research and development expenses of $24.23 million as the Phase 3 program scaled up, and selling, general and administrative expenses of $15.03 million. The company held $159.0 million in cash, cash equivalents and marketable securities at June 30, 2026 and estimates this will fund normal operations for at least 12 months. It also has significant CRO and CMO commitments to support the trial. After quarter-end, it raised additional capital through its at-the-market equity program and received Orphan Drug Designation for IKT-001 in PAH, which may provide tax credits, fee exemptions and potential market exclusivity if the product is approved.
Inhibikase Therapeutics reported second quarter 2026 results and clinical progress for its lead PAH candidate IKT-001. The company highlighted continued advancement of its single pivotal Phase 3 IMPROVE-PAH trial, with 26 country regulatory approvals and 43 clinical sites recently initiated. IKT-001 has shown favorable preclinical and Phase 1 data and received Orphan Drug Designation from the U.S. FDA.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $159.0 million. After quarter-end, Inhibikase sold 25,000,000 common shares to RA Capital Management through its ATM facility for $50 million in gross proceeds, and expects its capital resources to fund operations through topline Part B data from IMPROVE-PAH, assuming full and timely exercise of Series A and B warrants. For the quarter, net loss was $19.6 million, or $0.11 per share, compared with $9.9 million, or $0.11 per share a year earlier, driven by higher research and development expenses of $13.4 million and selling, general and administrative expenses of $7.7 million.
Inhibikase Therapeutics, Inc. (IKT) is reported to have 14,653,994 shares of common stock beneficially owned for Section 13(d) purposes by reporting persons including RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah, who expressly disclaim status as a group.
The Fund directly holds 6,970,000 shares of common stock and Pre-Funded Warrants exercisable for up to 18,030,000 shares, subject to a Beneficial Ownership Blocker that limits ownership to 9.99% of outstanding common stock. The Fund is currently prohibited from exercising the Pre-Funded Warrants to the extent such exercise would result in beneficial ownership of more than 7,683,994 shares of common stock.
The ownership percentage is based on 132,032,636 shares outstanding as of May 1, 2026, plus 25,000,000 shares issued to the Fund on July 10, 2026, less 18,030,000 shares surrendered in exchange for Pre-Funded Warrants on July 29, 2026, and giving effect to warrants exercisable within 60 days. Due to EDGAR field limits, Row 11 shows 9.9%. Voting and dispositive power over the securities is shared among the reporting persons, and several of them disclaim beneficial ownership beyond determining their Section 13(d) obligations.
Inhibikase Therapeutics, Inc. ten percent owner RA Capital Healthcare Fund, L.P. entered an Exchange Agreement on July 29, 2026, swapping 18,030,000 shares of Common Stock for a Pre-Funded Warrant exercisable for up to 18,030,000 shares at $0.001 per share. After this disposition, the Fund holds 6,970,000 shares of Common Stock. The Pre-Funded Warrant is immediately exercisable, has no expiration date, and includes a 9.99% beneficial ownership limitation for the Fund and its Attribution Parties. RA Capital Management, L.P., its general partner and principals Peter Kolchinsky and Rajeev Shah are also reporting persons and each disclaims beneficial ownership beyond respective pecuniary interests.
Inhibikase Therapeutics director Dennis N. Berman exercised stock options covering 21,854 shares of common stock on July 30, 2026 at an exercise price of $1.26 per share. The fully vested options were converted, leaving 0 options from this grant and 21,854 common shares held directly.